サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1758988

ヘッジホッグ経路阻害薬の世界市場

Hedgehog Pathway Inhibitors

出版日
ページ情報
英文 102 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.50円
ヘッジホッグ経路阻害薬の世界市場
出版日: 2025年06月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 102 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ヘッジホッグ経路阻害薬の世界市場は2030年までに12億米ドルに達する見込み

2024年に5億6,370万米ドルと推定されるヘッジホッグ経路阻害薬の世界市場は、2024～2030年の分析期間において12.9%のCAGRで成長し、2030年には12億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである基底細胞がんの適応症は、CAGR 14.1％を記録し、分析期間終了時には8億6,210万米ドルに達すると予測されます。急性骨髄性白血病の適応症セグメントの成長率は、分析期間中CAGR 9.8%と推定されます。

米国市場は1億4,820万米ドルと推定、中国はCAGR 12.0％で成長すると予測

米国のヘッジホッグ経路阻害薬市場は、2024年に1億4,820万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億8,050万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは12.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ12.0％と10.9％と予測されています。欧州では、ドイツがCAGR約9.3%で成長すると予測されています。

世界のヘッジホッグ経路阻害薬市場- 主要動向と促進要因のまとめ

なぜヘッジホッグ経路ががん研究の中心に急浮上しているのか？

ヘッジホッグ（Hh）シグナル伝達経路は、かつては主に胚発生で研究されていたが、がんとの闘いにおける重要な標的として浮上してきました。この経路は細胞の分化と組織のパターン形成に重要な役割を果たしているが、その異常な活性化は現在、基底細胞がん、髄芽腫、膵臓がんなど、いくつかの悪性腫瘍に関連しています。腫瘍の増殖と抵抗性の背後にある分子メカニズムが解明されるにつれて、ヘッジホッグ経路はがん幹細胞を維持し、腫瘍の再発を促進するというユニークな役割を担っていることが注目されています。病理学的な条件下で成体組織におけるヘッジホッグ経路の再活性化は、臨床的および薬学的な関心の波に拍車をかけています。SMO（Smoothened）のような主要タンパク質を阻害することで機能するHPI（ヘッジホッグ経路阻害薬）は、単独の治療薬としてだけでなく、化学療法、放射線療法、その他の標的治療との併用でも試験されています。

分子医学の進歩はHPI開発にどのような変化をもたらしているのか？

分子生物学、ゲノミクス、バイオインフォマティクスの最先端の発展により、ヘッジホッグ経路阻害薬の同定と精緻化が加速しています。薬剤開発戦略は、広範なスペクトルを持つ薬剤から、さまざまなレベルでヘッジホッグシグナル伝達を選択的に遮断する特異性の高い低分子やモノクローナル抗体へと進化しています。分子ドッキングと構造に基づく薬剤設計の革新は、既知の耐性変異を克服する次世代のSMO阻害剤の創出を可能にしました。さらに、研究者は現在、GLI転写因子などの経路の下流要素を標的としており、SMO阻害を回避する腫瘍を治療する道を開いています。コンパニオン診断とバイオマーカーはまた、患者選択を改善し、治療が経路依存性腫瘍にのみ投与されることを保証しています。これらの技術的飛躍的進歩は、HPIの臨床的有用性を拡大し、より個別化された腫瘍学へのアプローチを促進しています。

市場の関心を高めている治療領域と患者集団は？

基底細胞がんは依然としてHPIの最も確立された適応症であるが、現在進行中の臨床試験と調査により、HPIは他の固形がんにも応用されつつあります。髄芽腫のような小児脳腫瘍は、ヘッジホッグ経路変異の発生率が高く、HPIは治療法が限られている若年患者において特に有望な選択肢となっています。さらに、小細胞肺がん、膵臓腺がん、特定の血液悪性腫瘍など、がんがヘッジホッグ経路の関与について研究されています。これらの治療領域におけるアンメット・メディカル・ニーズ、特に耐性がんや再発がんに対するアンメット・メディカル・ニーズは、市場の注目を集める大きな要因となっています。さらに、多発性基底細胞がんを発症しやすいゴーリン症候群のような希少遺伝子疾患は、ニッチではあるが重要なセグメントです。製薬会社は、このような多様な患者層に対する有効性を高め、毒性を軽減するために、特殊な送達システムや併用レジメンの開発に積極的に取り組んでいます。

ヘッジホッグ経路阻害薬市場の成長を促進する要因は何か？

ヘッジホッグ経路阻害薬市場の成長は、いくつかの要因によって牽引されています。腫瘍の発生、進行、耐性メカニズムにおける経路の役割に対する理解が深まり、医薬品開発の新たなターゲットが生み出されています。世界のがん罹患率の上昇と標的治療への関心の高まりが相まって、HPIのような精密医薬品への需要が高まっています。進行中の臨床試験と、特に基底細胞がんと髄芽腫に対する規制当局の承認拡大は、市場の基盤をさらに強固なものにしています。ゲノミクスとバイオマーカー開発における技術的進歩は、患者の層別化を強化し、臨床現場においてこれらの阻害剤をより効果的に使用することを可能にしています。併用療法レジメンにおけるHPIの可能性も重要なドライバーであり、これらの併用療法は治療困難ながんの予後を改善することを目的としているからです。最後に、研究資金の増加、バイオテクノロジー企業間の戦略的提携、新興市場におけるがん医療へのアクセスの拡大が、世界のHPI市場を前進させています。

セグメント

適応症（基底細胞がん適応症、急性骨髄性白血病適応症）

調査対象企業の例

  • AbbVie
  • Amgen
  • AstraZeneca
  • Bayer
  • BeiGene
  • Bristol-Myers Squibb
  • Celsion Corporation
  • Cell Centric
  • CureTech
  • Curis, Inc.
  • Eli Lilly
  • Genentech（Roche）
  • GSK（GlaxoSmithKline）
  • Horizon Therapeutics
  • Incyte Corporation
  • Ionis Pharmaceuticals
  • Jazz Pharmaceuticals
  • Merck & Co.
  • Novartis
  • OncoOne
  • Puma Biotechnology
  • Sanofi
  • Stemline Therapeutics
  • Synta Pharmaceuticals
  • Teva Pharmaceutical
  • Vanda Pharmaceuticals

AI統合

検証された専門家によるコンテンツとAIツールにより、市場情報と競合情報を変革します。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP37067

Global Hedgehog Pathway Inhibitors Market to Reach US$1.2 Billion by 2030

The global market for Hedgehog Pathway Inhibitors estimated at US$563.7 Million in the year 2024, is expected to reach US$1.2 Billion by 2030, growing at a CAGR of 12.9% over the analysis period 2024-2030. Basal Cell Carcinoma Indication, one of the segments analyzed in the report, is expected to record a 14.1% CAGR and reach US$862.1 Million by the end of the analysis period. Growth in the Acute Myeloid Leukemia Indication segment is estimated at 9.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$148.2 Million While China is Forecast to Grow at 12.0% CAGR

The Hedgehog Pathway Inhibitors market in the U.S. is estimated at US$148.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$180.5 Million by the year 2030 trailing a CAGR of 12.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.0% and 10.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.3% CAGR.

Global Hedgehog Pathway Inhibitors Market - Key Trends & Drivers Summarized

Why Is the Hedgehog Pathway Suddenly at the Center of Cancer Research?

The hedgehog (Hh) signaling pathway, once primarily studied in embryonic development, has emerged as a critical target in the fight against cancer. This pathway plays a vital role in cell differentiation and tissue patterning, but its aberrant activation is now linked to several malignancies, including basal cell carcinoma, medulloblastoma, and pancreatic cancer. As researchers uncover more about the molecular mechanisms behind tumor growth and resistance, the hedgehog pathway is gaining attention for its unique role in sustaining cancer stem cells and promoting tumor recurrence. Its reactivation in adult tissues under pathological conditions has spurred a wave of clinical and pharmaceutical interest. Hedgehog pathway inhibitors (HPIs), which work by blocking key proteins like SMO (Smoothened), are being tested not just as standalone therapies, but also in combination with chemotherapy, radiotherapy, and other targeted treatments.

How Are Advances in Molecular Medicine Transforming HPI Development?

Cutting-edge developments in molecular biology, genomics, and bioinformatics have accelerated the identification and refinement of hedgehog pathway inhibitors. Drug development strategies have evolved from broad-spectrum agents to highly specific small molecules and monoclonal antibodies that selectively block hedgehog signaling at different levels. Innovations in molecular docking and structure-based drug design have enabled the creation of next-generation SMO inhibitors that overcome known resistance mutations. Additionally, researchers are now targeting downstream elements of the pathway such as GLI transcription factors, which opens up avenues to treat tumors that bypass SMO inhibition. Companion diagnostics and biomarkers are also improving patient selection, ensuring that treatments are administered only to those with pathway-driven tumors. These technological breakthroughs are expanding the clinical utility of HPIs and fostering a more personalized approach to oncology.

Which Therapeutic Areas and Patient Populations Are Fueling Market Interest?

While basal cell carcinoma remains the most established indication for hedgehog pathway inhibitors, ongoing trials and research are broadening their application into other solid tumors. Pediatric brain cancers, such as medulloblastoma, show a high incidence of hedgehog pathway mutations, making HPIs a particularly promising option in young patients with limited treatment alternatives. Additionally, cancers such as small cell lung carcinoma, pancreatic adenocarcinoma, and certain hematologic malignancies are being studied for hedgehog pathway involvement. The unmet medical need in these therapeutic areas-especially for resistant or relapsed cancers-is a major driver of market attention. Furthermore, rare genetic disorders like Gorlin syndrome, which predispose patients to developing multiple basal cell carcinomas, represent a niche but significant segment. Pharmaceutical companies are actively developing specialized delivery systems and combination regimens to enhance efficacy and reduce toxicity across these varied populations.

What Factors Are Driving the Growth of the Hedgehog Pathway Inhibitors Market?

The growth in the hedgehog pathway inhibitors market is driven by several factors. The increasing understanding of the pathway’s role in tumor initiation, progression, and resistance mechanisms has created new targets for drug development. Rising cancer incidence globally, coupled with a growing focus on targeted therapies, has increased the demand for precision medicines like HPIs. Ongoing clinical trials and expanding regulatory approvals, particularly for basal cell carcinoma and medulloblastoma, are further solidifying the market’s foundation. Technological advances in genomics and biomarker development are enhancing patient stratification, allowing more effective use of these inhibitors in clinical settings. The potential of HPIs in combination therapy regimens is also a significant driver, as these combinations aim to improve outcomes in hard-to-treat cancers. Finally, increased research funding, strategic partnerships among biotech firms, and expanding access to oncology care in emerging markets are collectively propelling the global hedgehog pathway inhibitors market forward.

SCOPE OF STUDY:

The report analyzes the Hedgehog Pathway Inhibitors market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Basal Cell Carcinoma Indication, Acute Myeloid Leukemia Indication)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • AbbVie
  • Amgen
  • AstraZeneca
  • Bayer
  • BeiGene
  • Bristol-Myers Squibb
  • Celsion Corporation
  • Cell Centric
  • CureTech
  • Curis, Inc.
  • Eli Lilly
  • Genentech (Roche)
  • GSK (GlaxoSmithKline)
  • Horizon Therapeutics
  • Incyte Corporation
  • Ionis Pharmaceuticals
  • Jazz Pharmaceuticals
  • Merck & Co.
  • Novartis
  • OncoOne
  • Puma Biotechnology
  • Sanofi
  • Stemline Therapeutics
  • Synta Pharmaceuticals
  • Teva Pharmaceutical
  • Vanda Pharmaceuticals

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Hedgehog Pathway Inhibitors - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Basal Cell Carcinoma Propels Market for Hedgehog Inhibitors
    • Expanding Oncology Research Focus Throws Spotlight on Hedgehog Signaling Pathway
    • FDA Approvals for Novel Indications Drive Commercial Growth Opportunities
    • Advancements in Precision Medicine Strengthen Business Case for Targeted Therapies
    • Clinical Trial Expansion in Solid Tumors Accelerates Pipeline Development
    • Orphan Drug Designation Incentives Spur Innovation in Rare Cancers
    • Increasing Collaborations Among Pharma Players Propel Market Entry and Licensing
    • High Unmet Needs in Metastatic and Resistant Tumors Expand Addressable Market
    • Biomarker-Based Patient Stratification Drives Drug Adoption in Oncology Settings
    • Combination Therapies With Immuno-Oncology Agents Generate Synergistic Demand
    • Competitive Pipeline Activity Intensifies Focus on Next-Gen Inhibitors
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hedgehog Pathway Inhibitors Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hedgehog Pathway Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Hedgehog Pathway Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Basal Cell Carcinoma Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Basal Cell Carcinoma Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Acute Myeloid Leukemia Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Acute Myeloid Leukemia Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hedgehog Pathway Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 8: USA Recent Past, Current & Future Analysis for Hedgehog Pathway Inhibitors by Indication - Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 9: USA 6-Year Perspective for Hedgehog Pathway Inhibitors by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication for the Years 2025 & 2030
  • CANADA
    • TABLE 10: Canada Recent Past, Current & Future Analysis for Hedgehog Pathway Inhibitors by Indication - Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 11: Canada 6-Year Perspective for Hedgehog Pathway Inhibitors by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication for the Years 2025 & 2030
  • JAPAN
    • Hedgehog Pathway Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 12: Japan Recent Past, Current & Future Analysis for Hedgehog Pathway Inhibitors by Indication - Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 13: Japan 6-Year Perspective for Hedgehog Pathway Inhibitors by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication for the Years 2025 & 2030
  • CHINA
    • Hedgehog Pathway Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 14: China Recent Past, Current & Future Analysis for Hedgehog Pathway Inhibitors by Indication - Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: China 6-Year Perspective for Hedgehog Pathway Inhibitors by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication for the Years 2025 & 2030
  • EUROPE
    • Hedgehog Pathway Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 16: Europe Recent Past, Current & Future Analysis for Hedgehog Pathway Inhibitors by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: Europe 6-Year Perspective for Hedgehog Pathway Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 18: Europe Recent Past, Current & Future Analysis for Hedgehog Pathway Inhibitors by Indication - Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Europe 6-Year Perspective for Hedgehog Pathway Inhibitors by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication for the Years 2025 & 2030
  • FRANCE
    • Hedgehog Pathway Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 20: France Recent Past, Current & Future Analysis for Hedgehog Pathway Inhibitors by Indication - Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: France 6-Year Perspective for Hedgehog Pathway Inhibitors by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication for the Years 2025 & 2030
  • GERMANY
    • Hedgehog Pathway Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 22: Germany Recent Past, Current & Future Analysis for Hedgehog Pathway Inhibitors by Indication - Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Germany 6-Year Perspective for Hedgehog Pathway Inhibitors by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication for the Years 2025 & 2030
  • ITALY
    • TABLE 24: Italy Recent Past, Current & Future Analysis for Hedgehog Pathway Inhibitors by Indication - Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Italy 6-Year Perspective for Hedgehog Pathway Inhibitors by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication for the Years 2025 & 2030
  • UNITED KINGDOM
    • Hedgehog Pathway Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 26: UK Recent Past, Current & Future Analysis for Hedgehog Pathway Inhibitors by Indication - Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: UK 6-Year Perspective for Hedgehog Pathway Inhibitors by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Hedgehog Pathway Inhibitors by Indication - Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Rest of Europe 6-Year Perspective for Hedgehog Pathway Inhibitors by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Hedgehog Pathway Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Hedgehog Pathway Inhibitors by Indication - Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Asia-Pacific 6-Year Perspective for Hedgehog Pathway Inhibitors by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 32: Rest of World Recent Past, Current & Future Analysis for Hedgehog Pathway Inhibitors by Indication - Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Rest of World 6-Year Perspective for Hedgehog Pathway Inhibitors by Indication - Percentage Breakdown of Value Sales for Basal Cell Carcinoma Indication and Acute Myeloid Leukemia Indication for the Years 2025 & 2030

IV. COMPETITION